Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Mandatory submission of patient identifiable information to third parties: FGM now, what next?

Bewley S, Kelly B, Darke K, Erskine K, Gerada C, Lohr P, de Zulueta P.

BMJ. 2015 Sep 30;351:h5146. doi: 10.1136/bmj.h5146. No abstract available.

PMID:
26424613
2.

The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study.

O'Callaghan FJ, Lux AL, Darke K, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, Verity CM, Osborne JP.

Epilepsia. 2011 Jul;52(7):1359-64. doi: 10.1111/j.1528-1167.2011.03127.x. Epub 2011 Jun 10.

3.

Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial.

Darke K, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Lux AL, Newton RW, O'Callaghan FJ, Verity CM, Osborne JP; trial steering committee on behalf of participating investigators.

Arch Dis Child. 2010 May;95(5):382-6. doi: 10.1136/adc.2009.160606.

PMID:
20457702

Supplemental Content

Support Center